Intermittent methionine restriction reduces IGF-1 levels and produces similar healthspan benefits to continuous methionine restriction.
Level 5 - mechanism / opinion, no new human data
Animal research (rodent model) with no human clinical data.
PubMed 35570387 · doi:10.1111/acel.13629
What was done
Researchers developed two increasingly stringent forms of intermittent methionine restriction (IMR) in mice to evaluate whether cyclical restriction replicates the benefits of continuous methionine restriction. They assessed metabolic markers including glucose homeostasis, protection against diet-induced obesity and hepatosteatosis, and plasma levels of IGF-1, FGF-21, leptin, and adiponectin.
What was found
The abstract reports no numerical values, sample sizes, or effect sizes. It reports qualitatively that IMR produced metabolic effects similar to continuous methionine restriction, including improved glucose homeostasis, reduced plasma IGF-1, altered levels of FGF-21, leptin, and adiponectin, and protection against diet-induced obesity and hepatosteatosis.
Why it matters
Continuous methionine restriction improves metabolic health and extends lifespan in rodents but is difficult for humans to maintain. Demonstrating that intermittent restriction yields comparable metabolic and endocrine benefits in mice suggests a potentially more feasible translational dietary strategy.
Limits
The study was conducted entirely in mice, so findings cannot be directly extrapolated to humans. The abstract omits sample sizes, dietary compositions, intervention durations, numerical values, statistical significance levels, and lifespan measurements.
Cited by
- supports Dietary proteins and specific amino acids such as methionine and cysteine regulate circulating IGF-1 levels in mammals.